TARGETED MEDICAL PHARMA
Targeted Medical Pharma Inc. ("TMP") is a leader in the development of therapeutic systems for the nutritional management of chronic diseases. The Company strives to optimize patient care with safe and clinically effective prescription Medical Foods, as well as distributing generic and branded drugs.
TARGETED MEDICAL PHARMA
Industry:
Biotechnology
Founded:
1999-01-01
Address:
Los Angeles, California, United States
Country:
United States
Website Url:
http://www.tmedpharma.com
Total Employee:
11+
Status:
Active
Contact:
310-474-9809
Email Addresses:
[email protected]
Technology used in webpage:
Domain Not Resolving Apache Google Apps For Business 1and1
Similar Organizations
Enobia Pharma
Enobia Pharma develops therapies for the treatment of serious genetic bone disorders.
Evoke Pharma
Evoke Pharma develops therapeutics for the treatment of gastrointestinal diseases.
Innovative Healthcare
Innovative Healthcare develops therapeutics for the treatment of diabetes and chronic wounds.
Stock Details
Official Site Inspections
http://www.tmedpharma.com Semrush global rank: 13.53 M Semrush visits lastest month: 88
- Host name: 74-208-236-80.elastic-ssl.ui-r.com
- IP address: 74.208.236.80
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Targeted Medical Pharma"
TME Pharma - About
TME Pharma . TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor …See details»
TME Pharma - Wikipedia
TME Pharma, formerly NOXXON Pharma, is a biotechnology company founded in 1997 in Berlin, Germany which specialises on cancer treatment by targeting the tumor microenvironment. TME Pharma N.V. is listed on Euronext Growth, Paris (ALTME)and is a member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller (vfa). See details»
October 2024 - TME Pharma
Www.tmepharma.com Aram Mangasarian, PhD, CEO Dr. Jarl-Ulf Jungnelius, CMO This document contains forward-looking statements. Please see prospectus, press releases and …See details»
TME Pharma N.V. - healthtechinnovationdays6.com
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor …See details»
TME Pharma - LinkedIn
TME Pharma | 3,837 followers on LinkedIn. Developing novel therapies for treatment of the most aggressive cancers by acting on the tumor microenvironment (TME) | TME Pharma is a …See details»
TME Pharma NV - Drug pipelines, Patents, Clinical trials - Synapse
Www.tmepharma.com. Public Company | 2015 | Germany | 10-50 | EPA: ALTME | www.tmepharma.com. Last update 01 Nov 2024. Overview. Pipeline. Deal. Translational …See details»
TME PHARMA PUBLISHES 2023 FINANCIAL RESULTS AND …
Is available on TME Pharma’s website (www.tmepharma.com). “2023 has been a year of significant clinical achievements which we believe have laid the foundations for the next steps …See details»
TME Pharma - VentureRadar
"TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor …See details»
TME Pharma: Contact Details and Business Profile
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor …See details»
TME Pharma Company Profile - Office Locations, Competitors
Oct 29, 2024 TME Pharma has 5 employees at their 1 location. See insights on TME Pharma including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
NOXXON PHARMA ANNOUNCES NAME CHANGE TO “TME …
[email protected] . Investor and Media Relations: LifeSci Advisors Guillaume van Renterghem Tel. +41 (0) 76 735 01 31 [email protected] NewCap Arthur …See details»
TME Pharma - Overview, News & Similar companies | ZoomInfo.com
Nov 28, 2022 TME Pharma Announces Appointment of Alexandra Glucksmann to Supervisory Board BERLIN--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth …See details»
TME Pharma Announces Results of Successful Capital Increase …
Dec 14, 2023 For more information on the Rights Issue, please consult the Rights Issue dedicated section on the TME Pharma website.. About TME Pharma. TME Pharma is a clinical …See details»
NOXXON Pharma Announces Name Change to “TME Pharma” and …
Jul 15, 2022 Contacts. For more information, please contact: TME Pharma N.V. Aram Mangasarian, Ph.D., CEO Bryan Jennings, CFO Tel. +49 (0) 30 726247 0 …See details»
TME Pharma Announces Further Improvement in Median Overall …
Dec 20, 2023 The NOX-A12-based combination with bevacizumab and radiotherapy has now further surpassed the median overall survival figures achieved in what TME Pharma believes …See details»
Improving Therapeutic Outcomes by Targeting the Tumor …
5 Median Overall Survival (mOS) 9.5 months n = 22 12.7 months 19.9 months Sources: Giordano (2022) ASCO Annual Meeting Presentation #2050; Giordano (2022) SNO Annual Meeting …See details»
TME Pharma Company Profile 2024: Stock Performance
TME Pharma General Information Description. TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor …See details»
TME PHARMA PUBLISHES AUDITED ANNUAL REPORT 2022
TME PHARMA PUBLISHES AUDITED ANNUAL REPORT 2022 • Financial visibility extended into December 2023 • Exceptional clinical results generated in brain cancer trial evaluating NOX …See details»
TME Pharma Announces Successful Advice Meeting With US Food …
Jan 9, 2024 Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME) (Paris:ALTME), a biotechnology company focused on developing novel therapies for treatSee details»
TME PHARMA ANNOUNCES APPOINTMENT OF ALEXANDRA …
[email protected] Investor and Media Relations: LifeSci Advisors Guillaume van Renterghem Tel. +41 (0) 76 735 01 31 [email protected] NewCap Arthur …See details»